Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1
- PMID: 33859413
- DOI: 10.1038/s41589-021-00783-w
Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1
Abstract
CUB domain-containing protein 1 (CDCP1) is an oncogenic orphan transmembrane receptor and a promising target for the detection and treatment of cancer. Extracellular proteolysis of CDCP1 by poorly defined mechanisms induces pro-metastatic signaling. We describe a new approach for the rapid identification of proteases responsible for key proteolytic events using a substrate-biased activity-based probe (sbABP) that incorporates a substrate cleavage motif grafted onto a peptidyl diphenyl phosphonate warhead for specific target protease capture, isolation and identification. Using a CDCP1-biased probe, we identify urokinase (uPA) as the master regulator of CDCP1 proteolysis, which acts both by directly cleaving CDCP1 and by activating CDCP1-cleaving plasmin. We show that coexpression of uPA and CDCP1 is strongly predictive of poor disease outcome across multiple cancers and demonstrate that uPA-mediated CDCP1 proteolysis promotes metastasis in disease-relevant preclinical in vivo models. These results highlight CDCP1 cleavage as a potential target to disrupt cancer and establish sbABP technology as a new approach to identify disease-relevant proteases.
Similar articles
-
Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1.Biol Chem. 2018 Sep 25;399(9):1091-1097. doi: 10.1515/hsz-2017-0308. Biol Chem. 2018. PMID: 29447112
-
The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention.Cancer Res. 2021 May 1;81(9):2259-2269. doi: 10.1158/0008-5472.CAN-20-2978. Epub 2021 Jan 28. Cancer Res. 2021. PMID: 33509939 Review.
-
Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.Oncogene. 2012 Aug 30;31(35):3924-38. doi: 10.1038/onc.2011.555. Epub 2011 Dec 19. Oncogene. 2012. PMID: 22179830 Free PMC article.
-
In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.Oncogene. 2014 Jan 9;33(2):255-68. doi: 10.1038/onc.2012.547. Epub 2012 Dec 3. Oncogene. 2014. PMID: 23208492 Free PMC article.
-
CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer.Life Sci. 2022 Jul 15;301:120600. doi: 10.1016/j.lfs.2022.120600. Epub 2022 May 2. Life Sci. 2022. PMID: 35504333 Review.
Cited by
-
Plasma proteomic profiles predict individual future health risk.Nat Commun. 2023 Nov 28;14(1):7817. doi: 10.1038/s41467-023-43575-7. Nat Commun. 2023. PMID: 38016990 Free PMC article.
-
The roles of proteases in prostate cancer.IUBMB Life. 2023 Jun;75(6):493-513. doi: 10.1002/iub.2700. Epub 2023 Jan 4. IUBMB Life. 2023. PMID: 36598826 Free PMC article. Review.
-
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.J Clin Invest. 2022 Feb 15;132(4):e154604. doi: 10.1172/JCI154604. J Clin Invest. 2022. PMID: 35166238 Free PMC article.
-
CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.Theranostics. 2022 Oct 3;12(16):6915-6930. doi: 10.7150/thno.78171. eCollection 2022. Theranostics. 2022. PMID: 36276654 Free PMC article.
-
A KLK6 Activity-Based Probe Reveals a Role for KLK6 Activity in Pancreatic Cancer Cell Invasion.J Am Chem Soc. 2022 Dec 14;144(49):22493-22504. doi: 10.1021/jacs.2c07378. Epub 2022 Nov 22. J Am Chem Soc. 2022. PMID: 36413626 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous